Dr. Bruce Eaton has been involved in commercial bioscience endeavors in Colorado and California for over 30 years in both therapeutics and human diagnostics leading to two successful IPOs. Bruce Eaton has to date founded four companies in the U.S. focused on pharmaceuticals, diagnostics and agrochemicals. He is currently a member of the Board of Directors of the Colorado Biosciences Association and the Colorado Institute for Drug Device and Diagnostic Development. He has held executive-level positions in six companies. As Vice President of Chemistry at NeXstar Pharmaceuticals, Bruce Eaton directed the efforts of over 50 scientists including the group responsible for the production of the first successful aptamer IND, NX1838 now known as Macugen (Eyetech Pharmaceuticals), marketed by Pfizer for age-related macular degeneration. Leading this chemistry effort, he was responsible for the acquisition and operation of chemistry companies in both the US and Europe. Bruce Eaton is an accomplished innovator with more than 70 patents issued worldwide. Dr. Eaton received his Ph.D. degree in Chemistry in 1988 from the University of California at Berkeley.